Therapeutic potential of melatonin and its analogs in Parkinson’s disease: focus on sleep and neuroprotection
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Sleep disorders constitute major nonmotor features of Parkinson’s disease (PD) that have a substantial effect on patients’ quality of life and can be related to the progression of the neurodegenerative disease. They can also serve as preclinical markers for PD, as it is the case for rapid eye movement (REM)-associated sleep behavior disorder (RBD). Although the etiology of sleep disorders in PD remains undefined, the assessment of the components of the circadian system, including melatonin secretion, could give therapeutically valuable insight on their pathophysiopathology. Melatonin is a regulator of the sleep/wake cycle and also acts as an effective antioxidant and mitochondrial function protector. A reduction in the expression of melatonin MT 1 and MT 2 receptors has been documented in the substantia nigra of PD patients. The efficacy of melatonin for preventing neuronal cell death and for ameliorating PD symptoms has been demonstrated in animal models of PD employing neurotoxins. A small number of controlled trials indicate that melatonin is useful in treating disturbed sleep in PD, in particular RBD. Whether melatonin and the recently developed melatonergic agents (ramelteon, tasimelteon, agomelatine) have therapeutic potential in PD is also discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phototransduction by retinal ganglion cells that set the circadian clock
Berson, D. M., Dunn, F. A., & Takao, M. (2002) · Science · doi:10.1126/science.1067262 · Cited by 3,629 · cited 1×
“Special photoreceptive retinal ganglion cells containing melanopsin as a photopigment are involved in the projection from retina [Berson et al. 2002; Brainard et al. 2001].”
BackgroundThe Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280 · cited 1×
“In addition, a dysfunctional blood brain barrier also appears to be involved in the progression of the disease [Monahan et al. 2008; Zlokovic, 2008; Kortekaas et al. 2005].”
BackgroundNon-motor symptoms of Parkinson's disease: diagnosis and management
Chaudhuri, K. R., Healy, D. G., & Schapira, A. H. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70373-8 · Cited by 2,807 · cited 2×
“Neuropsychiatric symptoms, such as vivid dreams, nightmares and nocturnal hallucinations, or RBD, are commonly observed in PD [Chaudhuri et al. 2006, 2002; Dhawan et al. 2006a, 2006b; Grandas and Iranzo, 2004].”
BackgroundDibner, C., Schibler, U., & Albrecht, U. (2010) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021909-135821 · Cited by 2,421
A systematic review of prevalence studies of depression in Parkinson's disease
Reijnders, J. S. A. M., Ehrt, U., Weber, W. E. J., Aarsland, D., & Leentjens, A. F. G. (2008) · Movement Disorders · doi:10.1002/mds.21803 · Cited by 1,239
Kondratov, R. V., Kondratova, A. A., Gorbacheva, V. Y., Vykhovanets, O. V., & Antoch, M. P. (2006) · Genes & Development · doi:10.1101/gad.1432206 · Cited by 1,188 · cited 1×
“Disruptions of Bmal1 and Per1 expression in mice brought about altered circadian behavior and dysregulation of circadian patterns in cell function [Kondratov et al. 2006; Cermakian et al. 2001].”
BackgroundTansey, M. G., & Goldberg, M. S. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.11.004 · Cited by 1,045
The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it
Fahn, S., & Cohen, G. (1992) · Annals of Neurology · doi:10.1002/ana.410320616 · Cited by 927 · cited 2×
“…generation of free radicals and the associated oxidative stress, which is enhanced in certain regions of the aging brain [Gibson et al. 2010; Fahn and Cohen, 1992; Olanow, 1992], antioxidants, such as vitamin E that attenuates 1-methyl-4phenyl-1,2,3,6 tetrahydropyridine (MPTP) Parkinsonism…”
BackgroundMelatonin: Nature’s most versatile biological signal?
Pandi‐Perumal, S. R., Srinivasan, V., Maestroni, G. J. M., Cardinali, D. P., Poeggeler, B., & Hardeland, R. (2006) · The FEBS Journal · doi:10.1111/j.1742-4658.2006.05322.x · Cited by 875 · cited 2×
“…occurs in various other regions of the body such as the gastrointestinal tract, skin, lymphocytes, platelets, bone marrow cells, retina, or thymus [Hardeland et al. 2011; Reiter et al. 2010; Pandi-Perumal et al. 2006b], in all of these tissues melatonin has either an autocrine or a paracrine role.”
BackgroundSelf-citationMelatonin—A pleiotropic, orchestrating regulator molecule
Hardeland, R., Cardinali, D. P., Srinivasan, V., Spence, D. W., Brown, G. M., & Pandi-Perumal, S. R. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.12.004 · Cited by 843
Self-citationClassic toxin-induced animal models of Parkinson?s disease: 6-OHDA and MPTP
Schober, A. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0938-y · Cited by 803
Blood–brain barrier dysfunction in parkinsonian midbrain in vivo
Kortekaas, R., Leenders, K. L., van Oostrom, J. C. H., Vaalburg, W., Bart, J., Willemsen, A. T. M., & Hendrikse, N. H. (2005) · Annals of Neurology · doi:10.1002/ana.20369 · Cited by 733
the Arizona Parkinson’s Disease Consortium, Beach, T. G., Adler, C. H., Lue, L., Sue, L. I., Bachalakuri, J., Henry-Watson, J., Sasse, J., Boyer, S., Shirohi, S., et al. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0538-8 · Cited by 698 · cited 2×
“At more advanced stages (4 6) cortical neurons become affected [Beach et al. 2009; Braak et al. 2007, 2003]. http://tan.sagepub.com 299 Despite some debates on the preclinical processes [Wu et al. 2011], there can be no doubt about a remarkably extended period of neurological changes prior to the…”
BackgroundArendt, J., & Skene, D. J. (2005) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2004.05.002 · Cited by 629 · cited 5×
“2005; Guerrero and Reiter, 2002] and regulation of circadian [Deacon and Arendt, 1995; Armstrong, 1989] and sleep/wake rhythms [Arendt and Skene, 2005; Rajaratnam et al. 2004].”
BackgroundInfluentialHypocretin (orexin) cell loss in Parkinson's disease
Thannickal, T. C., Lai, Y.-Y., & Siegel, J. M. (2007) · Brain · doi:10.1093/brain/awm097 · Cited by 566 · cited 1×
“A loss of orexin neurons and of cells secreting melaninconcentrating hormone in the hypothalamus of PD patients is said to be responsible for nocturnal insomnia, RBD and hallucinations [Thannickal et al. 2008, 2007].”
BackgroundThe Nighttime Problems of Parkinsonʼs Disease
Lees, A. J., Blackburn, N. A., & Campbell, V. L. (1988) · Clinical Neuropharmacology · doi:10.1097/00002826-198812000-00004 · Cited by 444
An introduction to the free radical hypothesis in Parkinson's disease
Olanow, C. W. (1992) · Annals of Neurology · doi:10.1002/ana.410320703 · Cited by 382 · cited 2×
“Although the increasing incidence of age-associated neurodegenerative diseases such as PD has been attributed to the augmented generation of free radicals and the associated oxidative stress, which is enhanced in certain regions of the aging brain [Gibson et al. 2010; Fahn and Cohen, 1992; Olanow, 1992], antioxidants,…”
BackgroundEffect of Psychiatric and Other Nonmotor Symptoms on Disability in Parkinson's Disease
Weintraub, D., Moberg, P. J., Duda, J. E., Katz, I. R., & Stern, M. B. (2004) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2004.52219.x · Cited by 381
Inhibition of mitochondrial respiratory complex I by nitric oxide, peroxynitrite and S-nitrosothiols
Brown, G. C., & Borutaite, V. (2004) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2004.03.016 · Cited by 344 · cited 2×
“NO, by reacting with O 2 generates the highly toxic peroxynitrite, an agent that impairs mitochondrial function and causes irreversible inhibition of all ETC complexes [Brown and Borutaite, 2004] and neuronal cell death [Zhang et al.”
BackgroundSelf-citationDepression and insomnia: questions of cause and effect
Lustberg, L., & Reynolds, C. F. (2000) · Sleep Medicine Reviews · doi:10.1053/smrv.1999.0075 · Cited by 300 · cited 1×
“Evidence from epidemiological and electroencephalographic studies implicate sleep disturbances as key factors in the pathogenesis of depressive illness [Lustberg and Reynolds, 2000].”
BackgroundAtomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease
Weintraub, D., Mavandadi, S., Mamikonyan, E., Siderowf, A. D., Duda, J. E., Hurtig, H. I., Colcher, A., Horn, S. S., Nazem, S., Ten Have, T. R., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181ebdd79 · Cited by 255 · cited 2×
“Drugs such as nortrypine and other SSRIs, which have been employed to treat 308 http://tan.sagepub.com depressive symptoms in PD, have not shown great effectiveness against the associated mood disturbances [Dobkin et al. 2010; Weintraub et al. 2010].”
BackgroundDijk, D., Shanahan, T. L., Duffy, J. F., Ronda, J. M., & Czeisler, C. A. (1997) · The Journal of Physiology · doi:10.1111/j.1469-7793.1997.851ba.x · Cited by 250 · cited 1×
“It is possible that melatonin feedbacks at the suprachiasmatic nucleus (SCN) to inhibit the circadian signal responsible for promoting wakefulness [Wehr et al. 2001; Dijk et al. 1997; Sack et al. 1992] (Figure 1).”
BackgroundAccuracy of sleep perceptions among insomnia sufferers and normal sleepers
Means, M. (2003) · Sleep Medicine · doi:10.1016/s1389-9457(03)00057-1 · Cited by 217 · cited 2×
“The findings that subjective more than objective findings of impaired sleep quality have a greater negative impact on life quality [Means et al. 2003] further suggest that PSG procedures may not be the best method for evaluating sleep disturbance in PD. Melatonin 3 12 mg at bedtime has been shown…”
BackgroundDeacon, S., & Arendt, J. (1995) · Brain Research · doi:10.1016/0006-8993(95)96872-i · Cited by 203
Expression of clock genes Per1 and Bmal1 in total leukocytes in health and Parkinson’s disease
Cai, Y., Liu, S., Sothern, R. B., Xu, S., & Chan, P. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2009.02848.x · Cited by 184
Evidence for a biological dawn and dusk in the human circadian timing system
Wehr, T. A., Aeschbach, D., & Duncan, W. C. (2001) · The Journal of Physiology · doi:10.1111/j.1469-7793.2001.t01-1-00937.x · Cited by 182
Sleep Disruption in Parkinson's Disease: Assessment by Continuous Activity Monitoring
van Hilten, B. (1994) · Archives of Neurology · doi:10.1001/archneur.1994.00540210094018 · Cited by 166 · cited 1×
“Treatment of PD with dopaminergic drugs has been shown to promote sleep when given in low doses, but when administered in higher doses it prolonged sleep latency and caused fragmentation of sleep [van Hilten et al. 1994].”
BackgroundPlasticity of the Intrinsic Period of the Human Circadian Timing System
Scheer, F. A. J. L., Wright, K. P., Kronauer, R. E., & Czeisler, C. A. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000721 · Cited by 146 · cited 1×
“Observations of subjects whose circadian rhythms had been experimentally desynchronized have supported the inference that REM sleep is driven by the circadian component whereas slow-wave sleep (SWS) (or non-REM sleep) is driven by the homeostatic component [Scheer et al. 2007].”
BackgroundMehta, S. H., Morgan, J. C., & Sethi, K. D. (2008) · CNS Spectrums · doi:10.1017/s1092852900017260 · Cited by 53
Sleep disorders and daytime sleepiness in Parkinson’s disease
Monderer, R., & Thorpy, M. (2009) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-009-0026-5 · Cited by 37
Cited by
Melatonin and inflammation-Story of a double-edged blade
Hardeland, R. (2018) · Journal of Pineal Research · doi:10.1111/jpi.12525 · Cited by 455
Self-citationSleep and Circadian Rhythm Regulation in Early Parkinson Disease
Breen, D. P., Vuono, R., Nawarathna, U., Fisher, K., Shneerson, J. M., Reddy, A. B., & Barker, R. A. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.65 · Cited by 440
Aging, melatonin, and the pro- and anti-inflammatory networks
Hardeland, R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20051223 · Cited by 337
Self-citationSchroeder, A. M., & Colwell, C. S. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.09.002 · Cited by 189
Sleep Medicine - Asleep or Awake?
(2024) · doi:10.5772/intechopen.104201 · Cited by 5
Metadata
- Authors
- Srinivasan, V., Cardinali, D. P., Srinivasan, U. S., Kaur, C., Brown, G. M., Spence, D. W., Hardeland, R., & Pandi-Perumal, S. R.
- Venue
- Therapeutic Advances in Neurological Disorders
- Publisher
- SAGE Publications
- Published
- 2011-07-04
- Volume
- 4
- Issue
- 5
- Pages
- 297-317
- ISSN
- 1756-2856 (ISSN-L)
- 1756-2864
- OpenAlex
- W2103958324
- Cited by
- 113
- References
- 30
- FWCI
- 4.76
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.